Risk assessment in the patient with established peripheral arterial disease

Abstract

Office-based cardiovascular risk prediction continues to challenge practitioners in primary and secondary risk stratification settings. In patients with established peripheral arterial disease (PAD), the risk of cardiovascular events (i.e. death or morbidity due to coronary heart disease and/or cerebrovascular disease) is high, yet traditional risk factors and the ankle—brachial index (ABI) do not provide a complete secondary risk prediction. In this population, office-based cardiovascular risk stratification may be improved by surrogate markers of the systemic atherosclerotic burden, as well as markers of systemic inflammation. This review will evaluate the utility of the ABI, clinical stage of disease, and the emerging role of C-reactive protein (CRP) and other inflammatory markers in secondary risk prediction in PAD. Defining which patients are in the highest category of risk may direct health care providers to emphasize secondary preventive measures, and facilitate patient adherence to recommended medical therapies and smoking cessation.

Keywords

atherosclerosis cardiovascular diseases C-reactive protein inflammation peripheral vascular diseases risk assessment

References

Kistorp C.

Risk stratification in secondary prevention: advances in multimarker profiles, or back to basics?

Circulation 2006 ; 114: 184—86.

Resnick HE , Lindsay RS , McDermott MM et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation 2004; 109: 733—39.

Diehm C. , Lange S. , Darius H. et al. Association of low ankle brachial index with high mortality in primary care. Eur Heart J 2006; 27: 1743—49.

Leng GC , Fowkes FG , Lee AJ , Dunbar J. , Housley E. , Ruckley CV Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. BMJ 1996; 313: 1440—44.

Grundy SM , Pasternak R. , Greenland P. , Smith S. Jr , Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology . Circulation 1999; 100: 1481—92.

Faxon DP , Creager MA , Smith SC Jr et al. Atherosclerotic Vascular Disease Conference: Executive summary: Atherosclerotic Vascular Disease Conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2004 ; 109: 2595—604.

Aboyans V. , Criqui MH

Can we improve cardiovascular risk prediction beyond risk equations in the physician's office?

J Clin Epidemiol 2006; 59: 547—58.

Newman AB , Siscovick DS , Manolio TA et al. Ankle—arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation 1993; 88: 837—45.

Zheng ZJ , Sharrett AR , Chambless LE et al. Associations of ankle—brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 1997; 131: 115—25.

10.

Abbott RD , Petrovitch H. , Rodriguez BL et al. Ankle/brachial blood pressure in men > 70 years of age and the risk of coronary heart disease. Am J Cardiol 2000; 86: 280—84.

11.

Menke A. , Muntner P. , Wildman RP , Dreisbach AW , Raggi P. Relation of borderline peripheral arterial disease to cardiovascular disease risk. Am J Cardiol 2006; 98: 1226—30.

12.

Agnelli G. , Cimminiello C. , Meneghetti G. , Urbinati S. Low ankle—brachial index predicts an adverse 1-year outcome after acute coronary and cerebrovascular events. J Thromb Haemost 2006; 4: 2599—606.

13.

Aboyans V. , Lacroix P. , Postil A. et al. Subclinical peripheral arterial disease and incompressible ankle arteries are both long-term prognostic factors in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol 2005; 46: 815—20.

14.

Beckman JA , Jaff MR , Creager MA

The United States Preventive Services Task Force recommendation statement on screening for peripheral arterial disease: more harm than benefit?

Circulation 2006; 114: 861—66.

15.

Hooi JD , Stoffers HE , Kester AD , van Ree JW , Knottnerus JA Peripheral arterial occlusive disease: prognostic value of signs, symptoms, and the ankle—brachial pressure index. Med Decis Making 2002; 22: 99—107.

16.

Beckman JA , Preis O. , Ridker PM , Gerhard-Herman M. Comparison of usefulness of inflammatory markers in patients with versus without peripheral arterial disease in predicting adverse cardiovascular outcomes (myocardial infarction, stroke, and death). Am J Cardiol 2005; 96: 1374—78.

17.

Mehler PS , Coll JR , Estacio R. , Esler A. , Schrier RW , Hiatt WR Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation 2003; 107: 753—56.

18.

Norgren L. , Hiatt WR , Dormandy JA , Nehler MR , Harris KA , Fowkes FG Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45(1S): S5—S67.

19.

Brevetti G. , Martone VD , Perna S. et al. Intermittent claudication and risk of cardiovascular events. Angiology 1998; 49: 843—48.

20.

Vogt MT , Cauley JA , Newman AB , Kuller LH , Hulley SB Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA 1993; 270: 465—69.

21.

McDermott MM , Feinglass J. , Slavensky R. , Pearce WH The ankle—brachial index as a predictor of survival in patients with peripheral vascular disease . J Gen Intern Med 1994; 9: 445—49.

22.

Howell MA , Colgan MP , Seeger RW , Ramsey DE , Sumner DS Relationship of severity of lower limb peripheral vascular disease to mortality and morbidity: a six-year follow-up study. J Vasc Surg 1989; 9: 691—97.

23.

Bowers BL , Valentine RJ , Myers SI , Chervu A. , Clagett GP The natural history of patients with claudication with toe pressures of 40mm Hg or less. J Vasc Surg 1993; 18: 506—11.

24.

O'Hare AM , Katz R. , Shlipak MG , Cushman M. , Newman AB Mortality and cardiovascular risk across the ankle—arm index spectrum: results from the Cardiovascular Health Study . Circulation 2006; 113: 388—93.

25.

Rutherford RB , Baker JD , Ernst C. et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997; 26: 517—38.

26.

Criqui MH , Langer RD , Fronek A. et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381—86.

27.

Schmieder FA , Comerota AJ Intermittent claudication: magnitude of the problem, patient evaluation, and therapeutic strategies. Am J Cardiol 2001; 87(12A): 3D—13D.

28.

Leng GC , Lee AJ , Fowkes FG et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 1996; 25: 1172—81.

29.

30.

Jelnes R. , Gaardsting O. , Hougaard JK , Baekgaard N. , Tonnesen KH , Schroeder T. Fate in intermittent claudication: outcome and risk factors. Br Med J (Clin Res Ed) 1986; 293: 1137—40.

31.

Dormandy J. , Mahir M. , Ascady G. et al. Fate of the patient with chronic leg ischaemia. A review article. J Cardiovasc Surg (Torino) 1989; 30: 50—57.

32.

Marston WA , Davies SW , Armstrong B. et al. Natural history of limbs with arterial insufficiency and chronic ulceration treated without revascularization. J Vasc Surg 2006; 44: 108—14.

33.

Pasqualini L. , Schillaci G. , Vaudo G. , Innocente S. , Ciuffetti G. , Mannarino E. Predictors of overall and cardiovascular mortality in peripheral arterial disease. Am J Cardiol 2001; 88: 1057—60.

34.

Brass EP , Anthony R. , Dormandy J. et al. Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia. J Vasc Surg 2006; 43: 752—59.

35.

Meijer WT , Hoes AW , Rutgers D. , Bots ML , Hofman A. , Grobbee DE Peripheral arterial disease in the elderly: The Rotterdam Study. Arterioscler Thromb Vasc Biol 1998; 18: 185—92.

36.

Weitz JI , Byrne J. , Clagett GP et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 1996; 94: 3026—49.

37.

Eagle KA , Rihal CS , Foster ED , Mickel MC , Gersh BJ Long-term survival in patients with coronary artery disease: importance of peripheral vascular disease. The Coronary Artery Surgery Study (CASS) Investigators . J Am Coll Cardiol 1994; 23: 1091—95.

38.

Cimminiello C. PAD. Epidemiology and pathophysiology. Thromb Res 2002; 106: V295—V301.

39.

Brevetti G. , Schiano V. , Verdoliva S. et al. Peripheral arterial disease and cardiovascular risk in Italy. Results of the Peripheral Arteriopathy and Cardiovascular Events (PACE) study. J Cardiovasc Med (Hagerstown ) 2006; 7: 608—13.

40.

Hirsch AT , Criqui MH , Treat-Jacobson D. et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286: 1317—24.

41.

Bhatt DL , Steg PG , Ohman EM et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180—89.

42.

Steg PG , Bhatt DL , Wilson PW et al. One-year cardiovascular event rates in outpatients with atherothrombosis . JAMA 2007; 297: 1197—206.

43.

Libby P. , Ridker PM , Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135—43.

44.

Wilson AM , Ryan MC , Boyle AJ The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen. Int J Cardiol 2006; 106: 291—97.

45.

Brevetti G. , Schiano V. , Chiariello M. Cellular adhesion molecules and peripheral arterial disease. Vasc Med 2006; 11: 39—47.

46.

Silvestro A. , Brevetti G. , Schiano V. , Scopacasa F. , Chiariello M. Adhesion molecules and cardiovascular risk in peripheral arterial disease. Soluble vascular cell adhesion molecule-1 improves risk stratification. Thromb Haemost 2005; 93: 559—63.

47.

Violi F. , Criqui M. , Longoni A. , Castiglioni C. Relation between risk factors and cardiovascular complications in patients with peripheral vascular disease. Results from the A.D.E.P. study . Atherosclerosis 1996; 120: 25—35.

48.

Torzewski M. , Rist C. , Mortensen RF et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000; 20: 2094—99.

49.

Vainas T. , Stassen FR , de Graff R. et al. C-reactive protein in peripheral arterial disease: relation to severity of the disease and to future cardiovascular events. J Vasc Surg 2005; 42: 243—51.

50.

Rossi E. , Biasucci LM , Citterio F. et al. Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: predictive role of C-reactive protein. Circulation 2002; 105: 800—803.

51.

Tsimikas S. , Willerson JT , Ridker PM C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol 2006; 47(8 suppl): C19—C31.

52.

Folsom AR , Chambless LE , Ballantyne CM et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med 2006 ; 166: 1368—73.

53.

Haverkate F. , Thompson SG , Pyke SD , Gallimore JR , Pepys MB Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group . Lancet 1997; 349: 462—66.

54.

Retterstol L. , Eikvar L. , Bohn M. , Bakken A. , Erikssen J. , Berg K. C-reactive protein predicts death in patients with previous premature myocardial infarction — a 10 year follow-up study. Atherosclerosis 2002; 160: 433—40.

55.

Wang TJ , Gona P. , Larson MG et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355: 2631—39.

56.

Danesh J. , Wheeler JG , Hirschfield GM et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387—97.

57.

Cushman M. , Arnold AM , Psaty BM et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the Cardiovascular Health Study. Circulation 2005; 112: 25—31.

58.

Pearson TA , Mensah GA , Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499—511.

59.

Owens CD , Ridker PM , Belkin M. et al. Elevated C-reactive protein levels are associated with postoperative events in patients undergoing lower extremity vein bypass surgery. J Vasc Surg 2007; 45: 2—9.

60.

Pasceri V. , Willerson JT , Yeh ET Direct proinflammatory effect of C-reactive protein on human endothelial cells . Circulation 2000; 102: 2165—68.

61.

Verma S. , Li SH , Badiwala MV et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002; 105: 1890—96.

62.

Li L. , Roumeliotis N. , Sawamura T. , Renier G. C-reactive protein enhances LOX-1 expression in human aortic endothelial cells: relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction . Circ Res 2004; 95: 877—83.

63.

Ross R. Atherosclerosis — an inflammatory disease. N Engl J Med 1999; 340: 115—26.

64.

Gokce N. , Keaney JF Jr , Hunter LM et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 2003; 41: 1769—75.

65.

Brevetti G. , Silvestro A. , Schiano V. , Chiariello M. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle—brachial pressure index. Circulation 2003; 108: 2093—98.

66.

Pellegrino T. , Storto G. , Filardi PP et al. Relationship between brachial artery flow-mediated dilation and coronary flow reserve in patients with peripheral artery disease. J Nucl Med 2005; 46: 1997—2002.

67.

Topol EJ , Smith J. , Plow EF , Wang QK Genetic susceptibility to myocardial infarction and coronary artery disease . Hum Mol Genet 2006;15 Spec No 2: R117—R123.

68.

Ridker PM , Cushman M. , Stampfer MJ , Tracy RP , Hennekens CH Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998 ; 97: 425—28.

69.

McDermott MM , Greenland P. , Green D. et al. D-dimer, inflammatory markers, and lower extremity functioning in patients with and without peripheral arterial disease. Circulation 2003; 107: 3191—98.

70.

McDermott MM , Liu K. , Guralnik JM et al. Functional decline in patients with and without peripheral arterial disease: predictive value of annual changes in levels of C-reactive protein and D-dimer. J Gerontol A Biol Sci Med Sci 2006; 61: 374—79.

71.

Giri J. , McDermott MM , Greenland P. et al. Statin use and functional decline in patients with and without peripheral arterial disease. J Am Coll Cardiol 2006; 47: 998—1004.